Skip to main content
Premium Trial:

Request an Annual Quote

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization granted on Friday emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports. China approved the vaccine from the state-owned Sinopharm in January.

The emergency approval adds a new vaccine to COVAX's arsenal, the Washington Post adds. COVAX was established earlier in the pandemic to enable global and equitable sharing of COVID-19 vaccines and made its first shipment in February. However, the effort has also been hindered by wealthier countries procuring vaccines directly from developers, rather than through the initiative, and by concerns over a lack of transparency.

"This expands the list of COVID-19 vaccines that COVAX can buy, and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine,” WHO director general Tedros Adhanom Ghebreyesus said during a Friday press briefing, according to the Post.

The Guardian adds that the WHO recommends the vaccine for adults 18 years and older in a two-dose regimen, though notes the analysis included few adults over the age of 65.

According to the Post, the emergency approval also bolsters the international stature of Sinopharm, as this is the first such approval given by the WHO to a Chinese-made vaccine.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.